Condition-specific role of colonic inflammatory molecules in persistent functional colorectal hypersensitivity in the mouse

Jun-Ho La, G. F. Gebhart

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: A low-level inflammation has been hypothesized to mediate visceral hypersensitivity in functional bowel disorders that persist after or even in the absence of gut inflammation. We aimed to test the efficacy of a steroidal anti-inflammatory treatment, and identify local inflammatory molecules mediating post- and non-inflammatory colorectal hypersensitivity using two mouse models. Methods: Visceromotor responses to colorectal distension were quantified as a measure of colorectal sensitivity. On day 1, mice received intracolonic saline (control), trinitrobenzenesulfonic acid (postinflammatory on day 15), or acidified hypertonic saline (non-inflammatory). Colorectal sensitivity before (day 10) and after (day 15) 4-day dexamethasone (Dex) treatment was compared, and colonic gene expression of inflammatory molecules was quantified. Key Results: Dexamethasone effectively inhibited gene expression of inflammatory molecules such as interleukin (IL)-1β and mast cell protease-1 in the colon, but did not attenuate colorectal hypersensitivity in either model. Gene expression of inflammatory molecules in the colon did not differ between control and the non-inflammatory model, but the postinflammatory model showed increased IL-10 and tight junction protein 2, and decreased IL-6, transforming growth factor (TGF)-β, a precursor of β-endorphin, occludin, and mucin 2. While no common molecule explained colorectal hypersensitivity in these models, hypersensitivity was positively correlated with TGF-β2 mRNA in control, and with IL-1β, inhibin βA, and prostaglandin E2 synthase in the Dex-treated postinflammatory model. In the non-inflammatory model, cyclooxygenase-2 mRNA was negatively correlated with colorectal sensitivity. Conclusions & Inferences: These results suggest that persistent functional colorectal hypersensitivity is mediated by condition-specific mediators whose gene expression in the colon is not inevitably sensitive to steroidal anti-inflammatory treatment. This study demonstrates the presence of condition-specific, steroid-insensitive inflammatory molecules in the colon for mediating persistent visceral hypersensitivity in post- and non-inflammatory conditions, suggesting multiple pathogenic players depending on disease conditions, and questioning effectiveness of steroid treatments on sensory symptoms in quiescent IBD and IBS.

Original languageEnglish (US)
Pages (from-to)1730-1742
Number of pages13
JournalNeurogastroenterology and Motility
Volume26
Issue number12
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

Hypersensitivity
Colon
Dexamethasone
Gene Expression
Transforming Growth Factors
Interleukin-1
Zonula Occludens-2 Protein
Mucin-2
Anti-Inflammatory Agents
Steroids
Trinitrobenzenesulfonic Acid
Inflammation
Occludin
Endorphins
Messenger RNA
Cyclooxygenase 2
Mast Cells
Interleukin-10
Interleukin-6
Peptide Hydrolases

Keywords

  • Colorectal hypersensitivity
  • Cytokines
  • Inflammation
  • Inflammatory molecules

ASJC Scopus subject areas

  • Endocrine and Autonomic Systems
  • Gastroenterology
  • Physiology
  • Medicine(all)

Cite this

Condition-specific role of colonic inflammatory molecules in persistent functional colorectal hypersensitivity in the mouse. / La, Jun-Ho; Gebhart, G. F.

In: Neurogastroenterology and Motility, Vol. 26, No. 12, 01.12.2014, p. 1730-1742.

Research output: Contribution to journalArticle

@article{5003abe55d76470e9959da44ba811307,
title = "Condition-specific role of colonic inflammatory molecules in persistent functional colorectal hypersensitivity in the mouse",
abstract = "Background: A low-level inflammation has been hypothesized to mediate visceral hypersensitivity in functional bowel disorders that persist after or even in the absence of gut inflammation. We aimed to test the efficacy of a steroidal anti-inflammatory treatment, and identify local inflammatory molecules mediating post- and non-inflammatory colorectal hypersensitivity using two mouse models. Methods: Visceromotor responses to colorectal distension were quantified as a measure of colorectal sensitivity. On day 1, mice received intracolonic saline (control), trinitrobenzenesulfonic acid (postinflammatory on day 15), or acidified hypertonic saline (non-inflammatory). Colorectal sensitivity before (day 10) and after (day 15) 4-day dexamethasone (Dex) treatment was compared, and colonic gene expression of inflammatory molecules was quantified. Key Results: Dexamethasone effectively inhibited gene expression of inflammatory molecules such as interleukin (IL)-1β and mast cell protease-1 in the colon, but did not attenuate colorectal hypersensitivity in either model. Gene expression of inflammatory molecules in the colon did not differ between control and the non-inflammatory model, but the postinflammatory model showed increased IL-10 and tight junction protein 2, and decreased IL-6, transforming growth factor (TGF)-β, a precursor of β-endorphin, occludin, and mucin 2. While no common molecule explained colorectal hypersensitivity in these models, hypersensitivity was positively correlated with TGF-β2 mRNA in control, and with IL-1β, inhibin βA, and prostaglandin E2 synthase in the Dex-treated postinflammatory model. In the non-inflammatory model, cyclooxygenase-2 mRNA was negatively correlated with colorectal sensitivity. Conclusions & Inferences: These results suggest that persistent functional colorectal hypersensitivity is mediated by condition-specific mediators whose gene expression in the colon is not inevitably sensitive to steroidal anti-inflammatory treatment. This study demonstrates the presence of condition-specific, steroid-insensitive inflammatory molecules in the colon for mediating persistent visceral hypersensitivity in post- and non-inflammatory conditions, suggesting multiple pathogenic players depending on disease conditions, and questioning effectiveness of steroid treatments on sensory symptoms in quiescent IBD and IBS.",
keywords = "Colorectal hypersensitivity, Cytokines, Inflammation, Inflammatory molecules",
author = "Jun-Ho La and Gebhart, {G. F.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1111/nmo.12455",
language = "English (US)",
volume = "26",
pages = "1730--1742",
journal = "Neurogastroenterology and Motility",
issn = "1350-1925",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Condition-specific role of colonic inflammatory molecules in persistent functional colorectal hypersensitivity in the mouse

AU - La, Jun-Ho

AU - Gebhart, G. F.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Background: A low-level inflammation has been hypothesized to mediate visceral hypersensitivity in functional bowel disorders that persist after or even in the absence of gut inflammation. We aimed to test the efficacy of a steroidal anti-inflammatory treatment, and identify local inflammatory molecules mediating post- and non-inflammatory colorectal hypersensitivity using two mouse models. Methods: Visceromotor responses to colorectal distension were quantified as a measure of colorectal sensitivity. On day 1, mice received intracolonic saline (control), trinitrobenzenesulfonic acid (postinflammatory on day 15), or acidified hypertonic saline (non-inflammatory). Colorectal sensitivity before (day 10) and after (day 15) 4-day dexamethasone (Dex) treatment was compared, and colonic gene expression of inflammatory molecules was quantified. Key Results: Dexamethasone effectively inhibited gene expression of inflammatory molecules such as interleukin (IL)-1β and mast cell protease-1 in the colon, but did not attenuate colorectal hypersensitivity in either model. Gene expression of inflammatory molecules in the colon did not differ between control and the non-inflammatory model, but the postinflammatory model showed increased IL-10 and tight junction protein 2, and decreased IL-6, transforming growth factor (TGF)-β, a precursor of β-endorphin, occludin, and mucin 2. While no common molecule explained colorectal hypersensitivity in these models, hypersensitivity was positively correlated with TGF-β2 mRNA in control, and with IL-1β, inhibin βA, and prostaglandin E2 synthase in the Dex-treated postinflammatory model. In the non-inflammatory model, cyclooxygenase-2 mRNA was negatively correlated with colorectal sensitivity. Conclusions & Inferences: These results suggest that persistent functional colorectal hypersensitivity is mediated by condition-specific mediators whose gene expression in the colon is not inevitably sensitive to steroidal anti-inflammatory treatment. This study demonstrates the presence of condition-specific, steroid-insensitive inflammatory molecules in the colon for mediating persistent visceral hypersensitivity in post- and non-inflammatory conditions, suggesting multiple pathogenic players depending on disease conditions, and questioning effectiveness of steroid treatments on sensory symptoms in quiescent IBD and IBS.

AB - Background: A low-level inflammation has been hypothesized to mediate visceral hypersensitivity in functional bowel disorders that persist after or even in the absence of gut inflammation. We aimed to test the efficacy of a steroidal anti-inflammatory treatment, and identify local inflammatory molecules mediating post- and non-inflammatory colorectal hypersensitivity using two mouse models. Methods: Visceromotor responses to colorectal distension were quantified as a measure of colorectal sensitivity. On day 1, mice received intracolonic saline (control), trinitrobenzenesulfonic acid (postinflammatory on day 15), or acidified hypertonic saline (non-inflammatory). Colorectal sensitivity before (day 10) and after (day 15) 4-day dexamethasone (Dex) treatment was compared, and colonic gene expression of inflammatory molecules was quantified. Key Results: Dexamethasone effectively inhibited gene expression of inflammatory molecules such as interleukin (IL)-1β and mast cell protease-1 in the colon, but did not attenuate colorectal hypersensitivity in either model. Gene expression of inflammatory molecules in the colon did not differ between control and the non-inflammatory model, but the postinflammatory model showed increased IL-10 and tight junction protein 2, and decreased IL-6, transforming growth factor (TGF)-β, a precursor of β-endorphin, occludin, and mucin 2. While no common molecule explained colorectal hypersensitivity in these models, hypersensitivity was positively correlated with TGF-β2 mRNA in control, and with IL-1β, inhibin βA, and prostaglandin E2 synthase in the Dex-treated postinflammatory model. In the non-inflammatory model, cyclooxygenase-2 mRNA was negatively correlated with colorectal sensitivity. Conclusions & Inferences: These results suggest that persistent functional colorectal hypersensitivity is mediated by condition-specific mediators whose gene expression in the colon is not inevitably sensitive to steroidal anti-inflammatory treatment. This study demonstrates the presence of condition-specific, steroid-insensitive inflammatory molecules in the colon for mediating persistent visceral hypersensitivity in post- and non-inflammatory conditions, suggesting multiple pathogenic players depending on disease conditions, and questioning effectiveness of steroid treatments on sensory symptoms in quiescent IBD and IBS.

KW - Colorectal hypersensitivity

KW - Cytokines

KW - Inflammation

KW - Inflammatory molecules

UR - http://www.scopus.com/inward/record.url?scp=84911955219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911955219&partnerID=8YFLogxK

U2 - 10.1111/nmo.12455

DO - 10.1111/nmo.12455

M3 - Article

VL - 26

SP - 1730

EP - 1742

JO - Neurogastroenterology and Motility

JF - Neurogastroenterology and Motility

SN - 1350-1925

IS - 12

ER -